Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Photo of pharmaceutical optical ampoule/vial inspection machine

Job Trends

California Manufacturing Jobs Dip But Still Key to State as Investment Continues

California’s life sciences manufacturing jobs dipped 3.7% in 2024, according to a new Biocom California report. Still, several companies made—and continuing making—significant manufacturing investments in the state as key trends shape the discipline.

July 2, 2025

2 min read

Angela Gabriel

Podcast

CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP

The high court sides with HHS on HIV PrEP drugs; Health Secretary RFK Jr.’s newly appointed CDC vaccine advisors discuss thimerosal in flu vaccines, skip vote on Moderna’s mRNA-based RSV vaccine; FDA removes CAR T guardrails; AbbVie snaps up Capstan for $1.2B to end first half; and psychedelics take off again with data from Compass and Beckley.

July 2, 2025

1 min read

Heather McKenzie

Businessman pulling a money bag down the cliff

Deals

Bluebird Go-Private Deal Signals the ‘PE-ization of Pharma’

Why did two private equity firms with more than $460 billion under management want a little old gene therapy biotech called bluebird bio? We wanted to know.

July 2, 2025

7 min read

Annalee Armstrong

Man reaching the top and having success, throwing cash in air. Being successful in finance concept. Vector illustration

Infectious disease

Gilead Eyes HIV Market Domination With Twice-Yearly Yeztugo as GSK Trails

Analysts believe that Gilead’s new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.

July 2, 2025

4 min read

Nick Paul Taylor

Illustration showing hand sweeping out half of employees

Layoffs

Biopharmas Continued Staff Cuts in 2025

While there had been hope layoffs would slow down in 2025, they continued at a fast pace, affecting even more people than in 2024, based on BioSpace tallies.

July 1, 2025

245 min read

BioSpace Editorial Staff

IN PARTNERSHIP WITH IQVIA

Understanding the FDA’s AI Guidance in Pharmacovigilance

In this episode presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses the FDA’s first draft guidance for AI in drug development, published in January 2025, with Archana Hegde, senior director, pv systems and innovations at IQVIA.

July 1, 2025

1 min read

Lori Ellis

Modern halftone collage. Concept of starting a new business, opening ceremony, launching a new product. Halftone hand cutting red ribbon with scissors symbolizing opening or starting a new. Modern business collage for design. Vector illustration

Cell therapy

CAR T Guardrail Removal Earns FDA Favor with CGT Community

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been attached to approved CAR T cancer therapies reflects “thoughtful consideration of real-world evidence” and “regulatory trust.”

July 1, 2025

6 min read

Heather McKenzie

Hand holding a nasal spray bottle against a white background

Psychedelics

Beckley’s Psychedelic Nasal Spray Clears Phase II Depression Study

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that the asset could hit peak market sales of $1 billion. The results clear the way for the asset’s late-stage development and for the completion of a proposed merger with atai Life Sciences.

July 1, 2025

2 min read

Tristan Manalac